# Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

> **NCT05054725** · PHASE2 · COMPLETED · sponsor: **Revolution Medicines, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** RMC-4630
- **DRUG:** Sotorasib

## Key facts

- **NCT ID:** NCT05054725
- **Lead sponsor:** Revolution Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-30
- **Primary completion:** 2024-07-03
- **Final completion:** 2024-08-29
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054725, "Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05054725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*